GCC Pharma Market Tops $30bn: CX Gaps in a Fast-Scaling Sector

What happened

The GCC pharmaceutical market surpassed $30 billion in 2025, driven primarily by accelerating life sciences investment in Saudi Arabia and the UAE, according to a new report from property and investment management firm JLL. The findings point to a structural expansion in healthcare infrastructure across the Gulf, as both governments channel capital into domestic pharmaceutical manufacturing, research facilities and distribution networks.

Saudi Arabia and the UAE are identified as the principal growth engines, with each country pursuing distinct but complementary strategies — Saudi Arabia through Vision 2030-aligned localisation of drug production, and the UAE through positioning itself as a regional hub for life sciences innovation and logistics. The JLL report frames this as a long-term structural shift rather than a cyclical uptick, suggesting the $30 billion figure represents a baseline from which further growth is anticipated.

Why it matters

For customer experience and service design practitioners, a rapidly expanding pharmaceutical market signals an equally rapid expansion in the patient and consumer touchpoints that sit around it — from pharmacy retail and digital health platforms to clinical trial recruitment and post-dispensing support. When markets scale at this pace, the infrastructure for physical product often outpaces the infrastructure for human experience, creating gaps in wayfinding, health literacy support, medication adherence and after-care communication that operators are frequently slow to close.

Behaviorally, healthcare consumers in high-growth markets face heightened complexity: more providers, more channels and more choices, all arriving faster than trust norms can be established. This is precisely the environment in which default bias, authority cues and friction at the point of care have an outsized influence on outcomes. Life sciences companies and healthcare operators entering or scaling in the GCC have a narrow window to design those defaults intentionally — before habits and expectations calcify around whatever experience happens to arrive first.

By the numbers

• $30 billion+ — the GCC pharmaceutical market valuation as of 2025, per the JLL report
• 2 markets — Saudi Arabia and the UAE — identified as the primary drivers of regional growth

The Renascence take

The headline number will attract real-estate developers, investors and policymakers — but the more consequential story for experience-led organisations is what a $30 billion market means for the millions of patients and consumers navigating it. Market size is not the same as market maturity, and in life sciences, that gap tends to show up most painfully at the human layer.

What most observers will miss is that pharmaceutical market growth in the GCC is simultaneously a patient-experience design challenge at scale. When supply expands faster than service literacy, the behavioral default is confusion and deferred trust — consumers delay, disengage or defer to whoever communicates most confidently, not most accurately. The operators who will define this market long-term are not those who simply distribute product, but those who invest now in the experience architecture around it: clear health communication, frictionless dispensing journeys, and post-purchase support that builds the kind of trust that sustains adherence. In a market still forming its habits, experience design is not a differentiator — it is the foundation.